These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

55 related articles for article (PubMed ID: 8174799)

  • 21. Inactivation of HIV, HBV, HCV related viruses and other viruses in human plasma derivatives by pasteurisation.
    Nowak T; Niedrig M; Bernhardt D; Hilfenhaus J
    Dev Biol Stand; 1993; 81():169-76. PubMed ID: 8174799
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Viral safety of solvent-detergent treated blood products.
    Horowitz B; Prince AM; Horowitz MS; Watklevicz C
    Dev Biol Stand; 1993; 81():147-61. PubMed ID: 8174797
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Theoretical and technical concerns in inactivation/elimination of viruses in plasma derivatives.
    Hilfenhaus J; Niedrig M; Nowak T
    Dev Biol Stand; 1993; 81():117-23. PubMed ID: 8174794
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Current safety of clotting factor concentrates.
    Epstein JS; Fricke WA
    Arch Pathol Lab Med; 1990 Mar; 114(3):335-40. PubMed ID: 2407224
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Chromatographic removal of viruses from plasma derivatives.
    Burnouf T
    Dev Biol Stand; 1993; 81():199-209. PubMed ID: 8174804
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Inactivation of AIDS-causing retroviruses by the manufacturing procedures for human plasma proteins.
    Hilfenhaus J; Gregersen JP
    Behring Inst Mitt; 1988 Apr; (82):82-93. PubMed ID: 3044347
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Understanding the pathogenesis and management of hepatitis B/HIV and hepatitis B/hepatitis C virus coinfection.
    Cheruvu S; Marks K; Talal AH
    Clin Liver Dis; 2007 Nov; 11(4):917-43, ix-x. PubMed ID: 17981235
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Reconstructing the origins of human hepatitis viruses.
    Simmonds P
    Philos Trans R Soc Lond B Biol Sci; 2001 Jul; 356(1411):1013-26. PubMed ID: 11516379
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Preventing the spread of hepatitis B and C viruses: where are germicides relevant?
    Sattar SA; Tetro J; Springthorpe VS; Giulivi A
    Am J Infect Control; 2001 Jun; 29(3):187-97. PubMed ID: 11391281
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pasteurized, monoclonal antibody factor VIII concentrate: establishing a new standard for purity and viral safety of plasma-derived concentrates.
    Goldsmith JC
    Blood Coagul Fibrinolysis; 2000 Mar; 11(2):203-15. PubMed ID: 10759015
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Lessons from HIV and hepatitis viruses.
    Sacks SL; Griffiths PD; Corey L; Cohen C; Cunningham A; Dusheiko GM; Self S; Spruance S; Stanberry LR; Wald A; Whitley RJ
    Antiviral Res; 2004 Aug; 63 Suppl 1():S11-8. PubMed ID: 15450381
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Genetic diversity-independent neutralization of pandemic viruses (e.g. HIV), potentially pandemic (e.g. H5N1 strain of influenza) and carcinogenic (e.g. HBV and HCV) viruses and possible agents of bioterrorism (variola) by enveloped virus neutralizing compounds (EVNCs).
    Kotwal GJ
    Vaccine; 2008 Jun; 26(24):3055-8. PubMed ID: 18241960
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Impact and management of hepatitis B and hepatitis C virus co-infection in HIV patients.
    Kumar R; Singla V; Kacharya Sk
    Trop Gastroenterol; 2008; 29(3):136-47. PubMed ID: 19115605
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [HIV safety of commercially produced human plasma proteins].
    Hilfenhaus J
    Infusionsther Transfusionsmed; 1994 Aug; 21 Suppl 1():84-8. PubMed ID: 8000262
    [TBL] [Abstract][Full Text] [Related]  

  • 35. At what stage should virus inactivation be carried out?
    Dorner F; Barrett PN; Eibl J
    Dev Biol Stand; 1993; 81():137-43. PubMed ID: 8174796
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Indications for fresh frozen plasma: evaluation of virus inactivating preparations].
    Pindur G; Kiesewetter H; Seyfert UT; Wenzel E
    Beitr Infusionsther; 1993; 31():74-80. PubMed ID: 7693268
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Inactivation of viruses and safety of stable plasma products.
    Morgenthaler JJ
    Beitr Infusionsther; 1989; 24():33-9. PubMed ID: 2481546
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Strategies for the validation of viral inactivation in biologic products.
    Aronson DL
    Prog Clin Biol Res; 1990; 324():137-49. PubMed ID: 2408050
    [No Abstract]   [Full Text] [Related]  

  • 39. Viral inactivation vs biological activity.
    Barrowcliffe TW
    Dev Biol Stand; 1993; 81():125-35. PubMed ID: 8174795
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Inactivation of viruses in fresh-frozen plasma.
    Wieding JU; Hellstern P; Köhler M
    Ann Hematol; 1993 Dec; 67(6):259-66. PubMed ID: 8280811
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 3.